博雅生物(300294.SZ):華潤集團將積極推動公司早日進入“國內血液製品第一梯隊”,並“成為世界一流的血液製品企業”
格隆匯5月22日丨博雅生物(300294.SZ)於2023年5月19日下午14:30-17:00參加投資者集體接待日活動,互動交流中,就“實控人華潤集團對公司有沒有進一步的扶持幫助計劃,或者是做大做強的規劃呢?”,公司回覆稱,華潤醫藥收購控股博雅生物,是華潤集團大健康領域的重要補充,填補了華潤集團血液製品業務的空白。華潤集團將以公司為血液製品平台,發展血液製品業務,積極推動公司早日進入“國內血液製品第一梯隊”,並“成為世界一流的血液製品企業”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.